#United States #Dublin #earnings report #Cardinal Health #Fiscal 2027

Overview of Cardinal Health's Q1 Fiscal Year 2027 Results

On November 5, 2026, Cardinal Health (NYSE: CAH) demonstrated a significant upward trajectory in their financial performance for the first quarter of fiscal year 2027. The company's revenue surged by 5% year-over-year, reaching an impressive $67.5 billion, while GAAP operating earnings jumped 13% to $753 million. Furthermore, the GAAP diluted earnings per share (EPS) showed a remarkable increase of 27%, hitting $2.38. This strong start has led the management to revise the non-GAAP EPS guidance for fiscal year 2027 upwards, now projected between $12.80 and $13.00.

Financial Performance Highlights

The first quarter results reveal a commendable growth in both GAAP and non-GAAP measures. To break it down:

• - Revenue: Increased from $64.0 billion in Q1 FY26 to $67.5 billion in Q1 FY27.
• - GAAP Operating Earnings: Climbed from $668 million to $753 million.
• - Non-GAAP Operating Earnings: Rose by 17% to $1.0 billion, reflecting strong operational efficiency and a favorable tax environment.
• - Net Earnings: From $450 million in Q1 FY26 to $554 million, marking a 23% increase.
• - Non-GAAP Net Earnings: Increased to $759 million from $611 million, yielding a 24% growth.

Both diluted and non-GAAP diluted EPS also experienced substantial growth, setting the tone for Cardinal Health's enhanced outlook. Given the effective tax rate adjustments—from 24.1% to 19.2%—the company benefitted significantly, further propelling net earnings growth.

Segment Analysis

A deeper analysis into Cardinal Health’s business segments reveals the following trends:
1. Pharmaceutical and Specialty Solutions: This segment saw revenues growing by 6%, reaching $62.6 billion, primarily due to robust sales in brand and specialty pharmaceuticals. Segment profit rose 17% to $783 million.
2. Global Medical Products and Distribution: Revenues remained relatively flat at $3.2 billion, with a notable dip in profit, which decreased to $33 million due to unfavorable exchange rates and market conditions.
3. Other Segments: Revenue climbed by 7% to $1.8 billion, driven by growth in Logistics and at-Home Solutions, with profits increasing by 16% to $193 million.

Strategic Decisions and Future Outlook

In light of their successful quarter, Cardinal Health is raising its FY 2027 non-GAAP diluted EPS guidance to a range of $12.80 to $13.00, anticipating a growth of 17% to 19% compared to FY26 baseline figures. Management attributes this upward revision to strategic investments, efficient operations, and an expansive product portfolio. Specific projections indicate a profit growth in the Pharmaceutical and Specialty Solutions from 10% to 12%, indicating improvement from prior expectations.

Another highlight is Cardinal Health's renewal of distribution agreements with CVS Health, reinforcing their strategic partnership and enabling volume growth in crucial segments. Moreover, the acquisition of AdaptHealth's Diabetes Health business, set to finalize in Q3 FY27, is expected to diversify Cardinal Health’s offerings further.

Insights from Management

CEO Jason Hollar stated, "Our results reflect a strong start to fiscal 2027 and demonstrate consistent execution against our strategic priorities. Internal operations and market conditions have propelled our growth, and we are optimistic about maintaining this momentum throughout the year."

Cardinal Health is also exploring innovative solutions, exemplified by the launch of their INSIGHT-IBD study in collaboration with Eli Lilly, aimed at understanding treatment patterns for inflammatory bowel disease (IBD) patients.

Concluding Thoughts

Cardinal Health’s first quarter results illuminate a robust company that is poised for recurring growth in fiscal year 2027 and beyond. With strategic investments and a steady focus on efficiency, it appears the company is gearing up to solidify its market position and enhance shareholder value. Investors can anticipate further discussions on the roadmap in the upcoming webcast scheduled for today at 8:30 a.m. ET, available through their Investor Relations page.